• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Organon & Co.

    < Previous 1 2 Next >
    Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Reports Results for the Third Quarter Ended September 30, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Reports Results for the Second Quarter Ended June 30, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Announces Pricing of $1.0 Billion Senior Notes Offering
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Announces Proposed $1.0 Billion Senior Notes Offering
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Reports Results for the First Quarter Ended March 31, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Reports Results for the Third Quarter Ended September 30, 2023
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    Organon Bolsters Research & Development Expertise with Two Leadership Appointments
    From Organon & Co.
    Via Business Wire
    Tickers OGN
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.